Metastatic Melanoma with Jason Luke, MD and Jeffrey Weber, MD, PhD: Case 1 - Episode 9
What impact have BRAF/MEK inhibitors had, since their initial approval, and how has this changed mutation testing for melanoma?
CASE: Metastatic Melanoma
Charles, a 62-year-old Caucasian landscaper, presented to his primary care physician with fatigue, dyspnea upon exertion, and a nonproductive cough that has lasted for 6 to 8 weeks. .
Treatment was initiated with the combination of BRAF and MEK inhibitors.